制药商艾伯维放弃抗病毒药专利权 
Abbvie, a drugmaker, has abandoned its patents on antiviral drugs
450字
2020-04-04 15:40
55阅读
火星译客

AbbVie is giving up its patents on a combination drug that is being studied as a coronavirus treatment, becoming the first major drugmaker to drop its rights to make money from a drug that might be used during the pandemic.

艾伯维(AbbVie)将要放弃一种正被研究用于治疗新型冠状病毒的复合药物的专利,成为首家对一种本来有望在大流行病期间畅销的药物放弃权益的大型制药商。

The US drugmaker will no longer enforce patents relating to Kaletra anywhere in the world for all formulations, according to the Medicines Patent Pool, a UN-backed non-governmental organisation.

The company gave notice of the change last week, according to a document seen by the Financial Times, after Israel moved to issue a compulsory licence for the drug combination’s use against the SARS-CoV2 coronavirus that is spreading worldwide.

据联合国(UN)支持的非政府组织——药品专利池组织(MPP)介绍,这家美国制药商将不再在世界任何地方对任何制剂执行与克力芝(Kaletra)相关的专利权。

英国《金融时报》看到的一份文件显示,该公司上周发出了变更通知,此前以色列采取行动,对这种复合药物用于抗击正在全球肆虐的新冠病毒SARS-CoV2颁发了强制许可。

Kaletra is a combination of two antivirals — lopinavir and ritonavir — and is usually used to treat HIV. But some doctors have turned to it for treating patients with coronavirus, and its efficacy is being studied in several clinical trials, including one by the World Health Organization.

克力芝是两种抗病毒药物——洛匹那韦(lopinavir)和利托那韦(ritonavir)——的复合制剂,通常用于治疗艾滋病毒(HIV)。但一些医生已开始用它治疗冠状病毒患者,其疗效正在几个临床试验中得到研究,包括世界卫生组织(WHO)的一个试验。

Stat News, a trade publication, reported last week that the company would allow Israel to purchase generic versions of the drug. AbbVie declined to comment.

行业刊物《Stat News》上周报道,该公司将允许以色列购买这种药物的仿制药版本。艾伯维拒绝置评。

The company had already donated a supply to the Chinese health authorities in January.

今年1月,该公司已经向中国卫生部门捐赠了一批药品。

What AbbVie has chosen to do “isn’t terribly common, certainly not globally”, said Ellen ‘t Hoen, director of Medicines Law & Policy, a non-governmental organisation. Kaletra has patent protection until at least 2026 in certain territories, according to MedsPaL, a database.

非政府组织Medicines Law & Policy的负责人艾伦•霍恩(Ellen 't Hoen)表示,艾伯维选择做的事情“并不很普遍,肯定不是全球性的”。数据库MedsPaL显示,克力芝在某些司法管辖区的专利保护至少要到2026年。

The pandemic has caused 12,000 deaths so far and infected nearly 300,000. There are no approved treatments.

到目前为止,这场大流行病已造成1.6万人死亡,30多万人确诊感染。目前尚无获得批准的治疗方法。

A Chinese study of Kaletra, which was published in the New England Journal of Medicine last week, showed disappointing results, with no effect on the progression of the disease.

上周发表于《新英格兰医学杂志》(New England Journal of Medicine)的一项关于克力芝的中国研究显示,结果令人失望,克力芝对病情的进展没有效果。

But for patients who started the drugs less than 12 days after their first symptoms, the mortality rate was 15 per cent, compared with 27 per cent over all, and the authors suggested it may work better if combined with other antiviral agents.

但对那些首次出现症状不到12天就开始用药的重症病人来说,死亡率是15%,而重症病人的整体死亡率为27%,且作者建议若将克力芝与其他抗病毒药物联合使用,效果可能会更好。

Pharmaceutical companies are racing to develop treatments and vaccines for the virus. So far, scientists have most hope for remdesivir, a drug developed by Gilead as a potential treatment for Ebola. Hospitals in the US are also stockpiling generic antimalarial drugs chloroquine and hydroxychloroquine, which have shown some positive impact in small studies.

制药公司正在竞相开发针对新冠病毒的治疗方法和疫苗。到目前为止,科学家们认为最有希望的药物是吉利德(Gilead)原本针对埃博拉病毒(Ebola)研发的瑞德西韦(remdesivir)。美国医院也在大量储备非专利抗疟药氯喹(chloroquine)和羟氯喹(hydroxychloroquine),这些药物在小规模研究中显示出一些积极的效果。

“AbbVie did the right thing,” said Ms ‘t Hoen. “But it foremost shows the power of the measure. Benefits will be immediate for people living with HIV, because generic supply is now possible everywhere in the world. The usefulness for Covid-19 still needs to be demonstrated and trials have started.”

“艾伯维做得对。”霍恩表示。“但最重要的是此举展示出威力。艾滋病毒感染者将立即受益,因为现在世界各地都可以提供仿制药。但克力芝治疗COVID-19是否有用仍有待证明,试验已经开始。”

0 条评论
评论不能为空